Home Business Life Sciences and Bio Pharma New Guidelines Set for Alzheim...

New Guidelines Set for Alzheimer’s Monoclonal Antibody Treatment

Life Sciences and Bio Pharma

Business Honor
20 May, 2025

Swiss guidelines set global precedent for Alzheimer’s care using advanced monoclonal antibody biologic therapies.

In a significant breakthrough in the treatment of Alzheimer's disease, the Swiss Memory Clinics (SMC) network has published Switzerland's first national guidelines for the clinical application of anti-amyloid monoclonal antibodies (mAbs) in treating Alzheimer's disease. Released in the April 11, 2025 edition of Neurodegenerative Diseases, a journal of Karger, the guidelines are a pivotal development at the intersection of life sciences and biopharma.

Recommendations are directed particularly toward the combination of Lecanemab and Donanemab new biologic drugs that target Alzheimer's-related amyloid plaques. Lecanemab has just been granted conditional approval by the European Commission, reflecting increasing regulatory support for mAbs in the treatment of neurodegenerative diseases.

This structure was created as a collaborative effort among neurologists, geriatricians, psychiatrists, neuropsychologists, neuroradiologists, and patient advocates. This structure places a strong focus on strict clinical practices such as biomarker confirmation, APOE genotyping, and ARIA (amyloid-related imaging abnormalities) monitoring through MRI, which are required for maintaining patient safety and therapeutic effect.

Major infrastructure needs, including trained staff, access to MRI, and monitoring after treatment, are also defined. Informed consent, ethical provision, and a national patient registry are the guidelines' emphasis—traits of a life sciences-based, data-driven paradigm of care.

These advances also mirror the growing contribution of the biopharma industry to the treatment of neurological disease. As biologics such as mAbs move from trials to actual clinical application, the SMC's efforts provide a model for how nations could implement such innovations responsibly.

Lead authors Prof. Giovanni B. Frisoni and Dr. Ansgar Felbecker said that they want to assist in shaping international adoption as Alzheimer's treatment moves into a new phase. The guidelines are anticipated to influence not only Swiss clinical practice but also more general regulatory and therapeutic standards within Europe and worldwide.